* If you want to update the article please login/register
This is a prospective single blinded controlled trial of a CIPN care scheme that integrates a personalised suite of remote symptom tracking services with real time responses from a nurse practitioner trained to implement an algorithmic guideline based CIPN therapy in response to poorly controlled conditions. In a 1:1 ratio to Usual Care or Symptom Care at Home with a Nurse Practitioner follow-up, participants with at least one day of any symptom that is moderate or higher on the NTSS6 will be randomised. The UC group will continue to see daily neuropathy symptoms via the web, app, or automated phone system and will receive standard care for CIPN symptoms from their current medical staff. The SCH-NP group will respond to similar symptoms, but moderate to severe signs may lead to a call back from a nurse practitioner who can perform interventions based on standardized algorithmic CIPN recommendations.
Source link: https://clinicaltrials.gov/ct2/show/NCT04763356
After complying with the other study eligibility criteria, subjects will be randomized into one of two treatment arms within 3 weeks of starting the offending chemotherapy agents. Arm 1 will be given INF twice a week for six weeks by the same treating physical therapist. Arm 2 will get a standardized muscle stretching and strengthening workout twice a week for six weeks under the supervision of treating physical therapist #1. Measurements used to determine the presence and extent of peripheral neuropathy in the population and severity of peripheral neuropathy will be administered by the same assessment physical therapist at baseline and three months after last physical therapy therapy. According to Arm 2 receiving standard care of muscle stretching and strengthening exercises based on standardized results, objective aims is to determine the degree of neuropathy and distress between Arm 1 and Arm 2 receiving INF therapy relative to Arm 2 receiving regular care of muscle stretching and strengthening exercises based on standardized results. Secondary goals: Objectives: For determining differences in vascular perfusion, the two treatment arms compare Ultrasound measurements of peak systolic velocity, volume flow, and pulsatility of popliteal and posterior tibia artery. Comparing Arm 1 receiving INF therapy to Arm 2 receiving a standardized program of muscle stretching and strengthening exercises, it is possible to determine the incidence of any dose reductions and premature chemotherapy discontinuation rates due to peripheral neuropathy. Based on a patient satisfaction survey administered at the end of care, we can compare subject acceptability, burden, and satisfaction with the assigned physical therapy modality between the two groups.
Source link: https://clinicaltrials.gov/ct2/show/NCT03272919
Since ancient times, Menthol has been used in conventional medicine as a topical pain reliever. Although these recommendations promote menthol use in patients with breast cancer, no studies have been published in the national and international literature examining the impact of topical menthol therapy in chemotherapy-induced peripheral neuropathy in patients with breast cancer. The aim of this research, which will be applied to breast cancer patients receiving chemotherapy, is to determine the effect of menthol application on CIPN. Menthol Application During the investigation, the patients' regular pharmacological therapy regimens would persist, and menthol will only be used to minimize the effects of neuropathy. According to the literature's recommendation, although it was reported in the studies that menthol had no side effects, it was decided to mix menthol with water-based cream. After the gram of the prepared mixture is determined, it will be given to the patients. Researchers will first determine how many grams of menthol will be appropriate by applying menthol to their hands and feet. Patients in the intervention group will be shown how to properly apply menthol cream to their hands and feet twice a day, every day. Patients with CIPN for three weeks immediately before and after 6 weeks of menthol therapy. This research will contribute to the literature and will have a major effect on many cancer patients and cancer survivors' quality of life.
Source link: https://clinicaltrials.gov/ct2/show/NCT05429814
Participants will enroll in a 6-week treatment program at one of nine Hands On Physical Therapy affiliated clinic locations listed in application to determine the effectiveness of direct current electrical stimulation on long-term signs and severity of neuropathy. Participants will then complete a specialized neuropathy program that includes traditional PT therapy for neuropathy, as well as surgery with the Neubie both during PT exercises and as additional therapy after sessions. The control group participants received 12 sessions of physical therapy over a 6-week cycle, including: a 30-min TENS injection in the feet and 15-min of various physical therapy exercises. Both the initial assessment and the final session will be evaluated, as well as a neuropathy pain questionnaire, and both quantitative and qualitative results on the severity of neuropathy complaints will be collected.
Source link: https://clinicaltrials.gov/ct2/show/NCT05442021
The purpose of this random controlled clinical trial was to determine the effects of massage therapy in colorectal cancer patients receiving chemotherapy on peripheral neuropathy and quality of life in the Akdeniz University outpatient chemotherapy unit. The patients in the massage group received a series of eflorence, petrisage, and surface fraction massage techniques on local areas of their body's foot, elbow-hand, and knee-leg -foot. The research nurse, who had classical massage training and certification, concluded a series of six days of massage therapy. The severity of peripheral sensory neuropathy was determined at week 16.
Source link: https://clinicaltrials.gov/ct2/show/NCT05433246
The use of oxaliplatin in the treatment of colorectal or pancreas cancer patients with severe sensorimotor neuropathy contributes to severe sensorimotor neuropathy, which has a dramatic effect on cancer survivors. But preclinical studies have found that donepezil could prevent and treat neuropathic symptoms in oxaliplatin-treated rats. The present research aims to determine the therapeutic effectiveness of donepezil on cancer survivors with oxaliplatin-induced peripheral neuropathy. In healthy volunteers that donepezil reduced the pain threshold caused by stimulation of the sural nerve, without severe adverse effects, according to a research. Two studies in patients with neuropathic pain found that donepezil elevates the analgesic effect of gabapentin. Finally, a case study revealed the analgesic effect of donepezil in painful Alzheimer's disease patients. A preclinical report reported that donepezil caused an antineuropathic reaction in diabetic mice with neuropathic pain. grade 22652 of colorectal or pancreas cancer patients treated with oxaliplatin-based chemotherapy for the treatment of OIPN in patients who have undergone oxaliplatin-based chemotherapy for the treatment of colorectal or pancreas cancer and have peripheral neuropathy of grade u22652. The primary endpoint of our methodological approach, which will help us to more accurately identify neuropathic signs and assess the therapeutic effects of donepezil on these signs, can be found on our questionnaire. After a minimum of 12 weeks of therapy, a response rate will be assessed only for Donepezil arm and compared to each treatment arm as a proof of concept study.
Source link: https://clinicaltrials.gov/ct2/show/NCT05254639
In tumor patients undergoing chemotherapy, chemotherapy-induced peripheral neuropathy is common. If it is established that vaping nerve electrical stimulation through ear skin can effectively treat CIPN, investigators are hoping that the vaping nerve electrical stimulation of ear skin can improve the pain and neurotoxicity scores of CIPN patients. It would be a simple and safe non-drug therapy with good application prospects.
Source link: https://clinicaltrials.gov/ct2/show/NCT05434403
ARM I: Patients apply cannabidiol cream topically to the affected areas twice a day for 14 days. Patients then apply placebo cream topically to the affected areas BID for 14 days. ARM II: Patients apply placebo cream topically to the affected areas of BID for 14 days. Patients are now injected cannabidiol cream topically into the affected areas BID for 14 days.
Source link: https://clinicaltrials.gov/ct2/show/NCT05388058
As follows: Group control: 20 adult breast cancer patients on Taxane's chemo protocol will be divided into three groups as follows: The participants will be randomly divided into three groups as follows: Group control: 20 adult breast cancer patients on Taxane chemo protocol will receive 200 ml normal saline over forty minutes before each chemotherapy session ends; group control: 20 adult breast cancer patients on Taxane will receive 200 ml normal saline over forty minutes prior to each chemotherapy patients on Taxane Infusion of lidocaine licetate in 20 adult breast cancer patients on Taxane's protocol will receive lidocaine IV infusion in 200ml saline over 40 minutes with a maximum upper limit of 200 mg per each chemotherapy session until the end of the cycle. Group lidocaine infusion : 20 adult breast cancer patients on Taxane's chemo protocol will receive lidocaine IV infusion in 20 adult breast cancer patients on Taxane 20 adult breast cancer patients on chemotherapy will take oral duloxetine tablet 30 mg once a day, beginning from the night pre chemotherapy session to the end of cycle. If any chosen patient complained of neuropathic pain during chemotherapy, the duloxetine dosage will be reduced to 60 mg per day until the end of the cycle. After every chemotherapy session, with no guarantee of neuropathic pain measured, an onset and characteristics of neuropathic pain will be measured by neuropathic pain scale after each chemotherapy session, which is expected to be one session per week for 12 weeks after the end of the chemotherapy protocol cycle. At the start and the end of the chemo protocol cycle for breast cancer patients, blood samples will be obtained.
Source link: https://clinicaltrials.gov/ct2/show/NCT04732455
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions